Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

THERAPEUTICSMD, INC.

(TXMD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/12/2021 10/13/2021 10/14/2021 10/15/2021 10/18/2021 Date
0.7225(c) 0.7474(c) 0.7441(c) 0.7207(c) 0.7377(c) Last
2 928 423 3 537 419 2 722 978 3 055 583 1 999 635 Volume
+4.60% +3.45% -0.44% -3.14% +2.36% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 97,8 M - -
Net income 2021 -157 M - -
Net Debt 2021 203 M - -
P/E ratio 2021 -1,84x
Yield 2021 -
Sales 2022 182 M - -
Net income 2022 -78,9 M - -
Net Debt 2022 154 M - -
P/E ratio 2022 -3,95x
Yield 2022 -
Capitalization 311 M 311 M -
EV / Sales 2021 5,25x
EV / Sales 2022 2,55x
Nbr of Employees 400
Free-Float 93,3%
More Financials
Company
TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products from pregnancy prevention through menopause. Its product pipeline includes IMVEXXY, BIJUVA, ANNOVERA, and prenatal vitamin product. The IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due... 
Sector
Pharmaceuticals
Calendar
11/10Earnings Release
More about the company
Ratings of TherapeuticsMD, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about THERAPEUTICSMD, INC.
10/15THERAPEUTICSMD : Announces Appointment of Mark Glickman as Chief Business Officer
BU
10/15TherapeuticsMD, Inc. Announces Appointment of Mark Glickman as Chief Business Officer
CI
10/01THERAPEUTICSMD, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/01TherapeuticsMD, Inc. Announces Separation of Edward Borkowski as Executive Vice Preside..
CI
09/20THERAPEUTICSMD, INC.(NASDAQGS : TXMD) dropped from S&P Pharmaceuticals Select Industry Ind..
CI
09/17THERAPEUTICSMD, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule ..
AQ
09/07THERAPEUTICSMD, INC. : Other Events (form 8-K)
AQ
09/02THERAPEUTICSMD : Therapeutics MD Is Urging Women to ‘Take Pause' During Menopause Aw..
BU
08/23THERAPEUTICSMD : Annovera Gets J Code From Centers for Medicare and Medicaid Services
MT
08/23THERAPEUTICSMD : Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public..
BU
08/23TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Publi..
CI
08/19INSIDER TRENDS : Insider Buying Continued with Purchase of TherapeuticsMD Shares
MT
08/13UPDATE : Sesen Bio Soars Ahead of FDA's Decision on Bladder Cancer Drug Application
MT
08/12SESEN BIO : Soars Following Chief Compliance Officer Appointment, Ahead of FDA Decision on..
MT
08/10THERAPEUTICSMD : Names Hugh O'Dowd as President
MT
More news
News in other languages on THERAPEUTICSMD, INC.

- No features available -

More news
Chart THERAPEUTICSMD, INC.
Duration : Period :
TherapeuticsMD, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERAPEUTICSMD, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,74 $
Average target price 4,75 $
Spread / Average Target 544%
EPS Revisions
Managers and Directors
Robert G. Finizio Chief Executive Officer & Director
Hugh O'Dowd President
James C. Darecca Chief Financial Officer
Tommy George Thompson Chairman
Sebastian Mirkin Chief Medical Officer
Sector and Competitors